Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mesothelioma, Malignant: early-phase trial registry
5 of 7 indexed Mesothelioma, Malignant trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Mesothelioma, Malignant: 7 US clinical trials tracked, 5 recruiting.
Mesothelioma, Malignant is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is TCR2 Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition mesothelioma-malignant
OPEN 5 | RECR 71% | LATE 0 | EARLY 6 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)
Mesothelioma, Malignant lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mesothelioma, Malignant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mesothelioma, Malignant is recruiting above its size-band peers.
5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Mesothelioma, Malignant research.
TCR2 Therapeutics accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Mesothelioma, Malignant trials plan to enrol fewer than 100 people.
Median target enrolment is 57 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Mesothelioma, Malignant research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04104776
SW-682 in Advanced Solid Tumors
SpringWorks Therapeutics
NCT06251310
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT06057935
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
NCT05568680
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
University of Chicago
NCT07126509
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT03907852
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT05451849
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Mesothelioma, Malignant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mesothelioma, Malignant trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mesothelioma, Malignant page
7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Mesothelioma, Malignant trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- TCR2 Therapeutics sponsors the most Mesothelioma, Malignant trials on record, review their full trial history before evaluating a specific study. See TCR2 Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mesothelioma, Malignant condition card totals 7 registered trials; most-linked intervention gavo-cel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.